Cannabis Science, Inc.
Cannabis Science, Inc. (OTC:CBIS) takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. Cannabis Science, Inc. works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Cannabis Science’s initial focus is on cancers, HIV/AIDS, and neurological conditions. Cannabis Science, Inc. is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
“Regulators suspended trading in its common stock due to its failure to file its financials as a “fully-reporting issuer,” according to Seeking Alpha.